The pharmacokinetics of metoprolol and its metabolites in dialysis patients. 1980

K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann

The kinetics of tritiated metoprolol and its metabolites have been determined after intravenous and oral administration in dialysis patients. The kinetic behaviour of metoprolol in these patients does not differ from that in healthy volunteers, since its elimination depends on hepatic metabolism. The pharmacologically less active metabolite alpha-hydroxymetoprolol is formed to an individually varying degree and its half-life is prolonged. The concentration of the total radioactivity, which represents the sum of all metabolites, does not decline in the dialysis interval. During haemodialysis, however, its concentration decreases with a half-life of 5h. It might be assumed, that dialysis of these polar compounds is rather nonspecific and that it depends essentially on the dialysis technique.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
March 1981, British journal of clinical pharmacology,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
August 1997, European journal of cancer (Oxford, England : 1990),
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
April 2015, British journal of clinical pharmacology,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
June 2000, Archives of pharmacal research,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
January 2019, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
December 1988, Clinical pharmacokinetics,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
February 1988, The Journal of antimicrobial chemotherapy,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
January 1991, American journal of clinical oncology,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
September 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
K U Seiler, and K J Schuster, and G J Meyer, and W Niedermayer, and O Wassermann
January 1983, European journal of clinical pharmacology,
Copied contents to your clipboard!